Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Takara Bio Inc. ( (JP:4974) ).
Takara Bio Inc. has revised its financial forecasts for the first half of the fiscal year ending March 31, 2026, due to a global downturn in the life sciences research market and reduced research grants, particularly from the U.S. and China. The company anticipates a significant decline in net sales and profits, alongside recognizing an extraordinary loss of approximately ¥3.9 billion due to the termination of a joint development agreement and shifts in client strategies, and a reversal of deferred tax assets by ¥400 million.
The most recent analyst rating on (JP:4974) stock is a Hold with a Yen953.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.
More about Takara Bio Inc.
Takara Bio Inc. operates in the life sciences industry, focusing on products and services related to biotechnology research and development. The company is involved in areas such as cell processing and viral vectors, with a market focus on regenerative and gene therapy fields.
Average Trading Volume: 392,550
Technical Sentiment Signal: Hold
Current Market Cap: Yen116.8B
Learn more about 4974 stock on TipRanks’ Stock Analysis page.